|
2021 Journal Article Correction to: Prospective intra‑individual blinded comparison of [18F]PSMA‑1007 and [68 Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 10.1007/s00259-021-05520-y)Pattison, David A., Debowski, Maciej, Gulhane, Brook, Arnfield, Evyn G., Pelecanos, Anita M., Garcia, Peter L., Latter, Melissa J., Lin, Charles Y., Roberts, Matthew J., Ramsay, Stuart C. and Thomas, Paul A. (2021). Correction to: Prospective intra‑individual blinded comparison of [18F]PSMA‑1007 and [68 Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 10.1007/s00259-021-05520-y). European Journal of Nuclear Medicine and Molecular Imaging, 49 (2), 789-789. doi: 10.1007/s00259-021-05548-0 |
|
2021 Journal Article Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancerPattison, David A., Debowski, Maciej, Gulhane, Brook, Arnfield, Evyn G., Pelecanos, Anita M., Garcia, Peter L., Latter, Melissa J., Lin, Charles Y., Roberts, Matthew J., Ramsay, Stuart C. and Thomas, Paul A. (2021). Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 49 (2), 763-776. doi: 10.1007/s00259-021-05520-y |
|
2020 Journal Article Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case reportDhanani, Jayesh, Pattison, David A., Burge, Matthew, Williams, Julian, Riedel, Bernhard, Hicks, Rodney J. and Reade, Michael C. (2020). Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. Journal of Critical Care, 60, 319-322. doi: 10.1016/j.jcrc.2020.08.011 |
|
2020 Journal Article The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CTDudoignon, David, Pattison, David A., Legallois, Damien, Hicks, Rodney J. and Aide, Nicolas (2020). The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. Cancer Imaging, 20 (1) 68, 1-12. doi: 10.1186/s40644-020-00344-9 |
|
2020 Journal Article 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerRoberts, Matthew J., Morton, Andrew, Donato, Peter, Kyle, Samuel, Pattison, David A., Thomas, Paul, Coughlin, Geoff, Esler, Rachel, Dunglison, Nigel, Gardiner, Robert A., Doi, Suhail A., Emmett, Louise and Yaxley, John (2020). 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48 (2), 655-656. doi: 10.1007/s00259-020-04944-2 |
|
2020 Journal Article Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancerViolet, John, Sandhu, Shahneen, Iravani, Amir, Ferdinandus, Justin, Sue-Ping Thang, , Kong, Grace, Kumar, Aravind Ravi, Akhurst, Tim, Pattison, David, Beaulieu, Alexis, Mooi, Jennifer, Tran, Ben, Guo, Christina, Kalff, Victor, Murphy, Declan G., Jackson, Price, Eu, Peter, Scalzo, Mark, Williams, Scott G., Hicks, Rod J., Hofman, Michael S. and Tran, Ben (2020). Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 61 (6), 857-865. doi: 10.2967/jnumed.119.236414 |
|
2020 Journal Article Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate CancerViolet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S. P., Kong, G., Kumar, A. Ravi, Akhurst, T., Pattison, D. A., Beaulieu, A., Mooi, J., Guo, C., Kalff, V., Murphy, D. G., Jackson, P., Eu, P., Scalzo, M., Williams, S., Hicks, R. J. and Hofman, M. S. (2020). Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer. Journal of Urology, 203 (5). doi: 10.1097/JU.0000000000000779.01 |
|
2018 Journal Article 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapyHicks, Rodney J., Jackson, Price, Kong, Grace, Ware, Robert E., Hofman, Michael S., Pattison, David A., Akhurst, Timothy A., Drummond, Elizabeth, Roselt, Peter, Callahan, Jason, Price, Roger, Jeffery, Charmaine M., Hong, Emily, Noonan, Wayne, Herschtal, Alan, Hicks, Lauren J., Hedt, Amos, Harris, Matthew, Paterson, Brett M. and Donnelly, Paul S. (2018). 64Cu-SARTATE PET imaging of patients with neuroendocrine tumors demonstrates high tumor uptake and retention, potentially allowing prospective dosimetry for peptide receptor radionuclide therapy. Journal of Nuclear Medicine, 60 (6), 777-785. doi: 10.2967/jnumed.118.217745 |
|
2018 Journal Article Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imagingTang, Victor, Campbell, Patrina and Pattison, David A. (2018). Lymphangitic carcinomatosis from prostate cancer identified with gallium-68 prostate-specific membrane antigen positron emission tomography imaging. Urology, 114, e1-e2. doi: 10.1016/j.urology.2017.12.010 |
|
2018 Journal Article Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumorsLadwa, Rahul, Wen Hong, Hooi, Wyld, David, Pattison, David A. and Burge, Matthew (2018). Tumor cystic necrosis following peptide receptor radionuclide therapy in neuroendocrine tumors. Clinical Nuclear Medicine, 43 (3), 186-187. doi: 10.1097/RLU.0000000000001970 |
|
2018 Journal Article Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and68Ga-DOTATATE PET/CTBongetti, Elisa, Lee, Melissa H., Pattison, David A., Hicks, Rodney J., Norris, Richard, Sachithanandan, Nirupa and MacIsaac, Richard J. (2018). Diagnostic challenges in a patient with an occult insulinoma:68 Ga-DOTA-exendin-4 PET/CT and68Ga-DOTATATE PET/CT. Clinical Case Reports, 6 (4), 719-722. doi: 10.1002/ccr3.1448 |
|
2018 Journal Article Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imagingMossman, Anna K., Pattison, David A., Hicks, Rodney J., Hamblin, Peter S. and Yates, Christopher J. (2018). Localisation of occult extra-pancreatic insulinoma using glucagon-like peptide-1 receptor molecular imaging. Internal Medicine Journal, 48 (1), 97-98. doi: 10.1111/imj.13664 |
|
2017 Journal Article Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and PheochromocytomaKong, Grace, Grozinsky-Glasberg, Simona, Hofman, Michael S., Callahan, Jason, Meirovitz, Amichay, Maimon, Ofra, Pattison, David A., Gross, David J. and Hicks, Rodney J. (2017). Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. The Journal of Clinical Endocrinology & Metabolism, 102 (9), 3278-3287. doi: 10.1210/jc.2017-00816 |
|
2016 Journal Article High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumoursKong, Grace, Callahan, Jason, Hofman, Michael S., Pattison, David A., Akhurst, Tim, Michael, Michael, Eu, Peter and Hicks, Rodney J. (2016). High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 44 (3), 476-489. doi: 10.1007/s00259-016-3527-x |
|
2016 Journal Article THYROPET Study: Is It Biology or Technology That Is the Issue?Pattison, David A. and Hicks, Rodney J. (2016). THYROPET Study: Is It Biology or Technology That Is the Issue?. Journal of Nuclear Medicine, 58 (2), 354-354. doi: 10.2967/jnumed.116.181420 |
|
2016 Journal Article 68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneityChang, Chian A., Pattison, David A., Tothill, Richard W., Kong, Grace, Akhurst, Tim J., Hicks, Rodney J. and Hofman, Michael S. (2016). 68Ga-DOTATATE and 18F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. Cancer Imaging, 16 (1) 22. doi: 10.1186/s40644-016-0084-2 |
|
2016 Journal Article Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin : FDG-Avid Pituitary & Intravascular LymphomaPattison, David A., Hofman, Michael S., Bazargan, Ali, Colman, Peter and Hicks, Rodney J. (2016). Intense focal pituitary FDG uptake due to intravascular large B-cell lymphoma in pyrexia of unknown origin : FDG-Avid Pituitary & Intravascular Lymphoma. American Journal of Hematology, 91 (11), 1167-1168. doi: 10.1002/ajh.24469 |
|
2016 Journal Article A New Theranostic Paradigm for Advanced Thyroid CancerPattison, David A., Solomon, Benjamin and Hicks, Rodney J. (2016). A New Theranostic Paradigm for Advanced Thyroid Cancer. Journal of Nuclear Medicine, 57 (10), 1493-1494. doi: 10.2967/jnumed.116.173534 |
|
2015 Journal Article Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine MalignanciesPattison, David A. and Hofman, Michael S. (2015). Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. PET Clinics, 10 (4), 461-476. doi: 10.1016/j.cpet.2015.05.005 |
|
2015 Journal Article Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosisPattison, David A., Westcott, James, Lichtenstein, Meir, Toh, H.B., Gunawardana, Dishan, Better, Nathan, Forehan, Simon and Sivaratnam, Dinesh (2015). Quantitative assessment of thyroid-to-background ratio improves the interobserver reliability of technetium-99m sestamibi thyroid scintigraphy for investigation of amiodarone-induced thyrotoxicosis. Nuclear Medicine Communications, 36 (4), 356-362. doi: 10.1097/mnm.0000000000000260 |
